Skip to content
Established 1991 Linden, New Jersey · 908-975-0250
Lark Research High Quality Independent Investment Research

Commentary and analysis

Risk/Reward

Independent perspectives on companies, industries, investment sectors, and financial markets.

August 20, 2024Health Care · OGN

Organon (OGN) 24Q2 Update

24Q2 revenues were $1.607 billion, down 0.1% year-over-year, but up 2% at constant currency.  GAAP diluted EPS was $0.76, below 23Q2’s $0.95, but above my estimate of $0.67.  Non-GAAP EPS of $1.12 was behind last year’s $1.31, but…

Continue reading →
August 20, 2024GEHC · Health Care

GE Healthcare (GEHC) 24Q2 Update

GE Healthcare Technologies (GEHC) reported 24Q2 revenues of $4.84 billion, up 0.5% YOY and but 1.9% below my estimate.  Excluding currency and acquisitions, revenue increased 1%.  Revenues declined in all segments, except PDx, which rose 12.5%.  Sales in…

Continue reading →
August 20, 2024Health Care · PFE

Pfizer (PFE) 24Q2 Update

Pfizer (PFE) reported 24Q2 revenues of $13.3 billion, up 4% from 23Q2, but 4.5% below my estimate.  The shortfall from projections was due mostly to lower than expected sales of Comirnaty, Prevnar, Paxlovid and Abrysvo.  Pfizer’s GAAP EPS…

Continue reading →
August 20, 2024Industrials · MG

Mistras Group (MG) 24Q2 Update

Mistras Group reported 24Q2 EPS of $0.20 vs. 23Q2’s $0.01 and my estimate of $0.11.  Revenues of $189.8 million were up 7.8%, with all industry segments posting gains, including double-digit gains in segments that had been experiencing steady…

Continue reading →
August 7, 2024Health Care · MRK

Merck & Co (MRK) 24Q2 Update

24Q2 sales increased 7.2% to $16.1 billion.  Excluding currency, sales rose 11%.  The sales gain came almost entirely from an increase of $1.0 billion in Keytruda.  However, a few recently launched medicines posted solid sales, including Wellireg, Winrevair…

Continue reading →
August 7, 2024T · Telecommunications

AT&T (T) 24Q2 Update

AT&T reported 24Q2 GAAP EPS of $0.49, below last year’s $0.62 and my estimate was $0.58.  Non-GAAP EPS was $0.57, below last year’s $0.63 and my estimate of $0.62.  Free cash flow was $4.6 billion in the quarter,…

Continue reading →
August 7, 2024BKR · Energy

Baker Hughes (BKR) 24Q2 Update

BKR reported 24Q2 GAAP diluted EPS of $0.58 vs. 23Q2’s $0.40 and my estimate of $0.47.  Non-GAAP EPS was $0.57 compared with $0.39 last year and my estimate of $0.48.  Revenues of $7.5 billion rose 13.1% vs. 23Q2,…

Continue reading →
June 20, 2024Health Care · OGN

Organon (OGN) 24Q1 Update

24Q1 revenues were $1.622 billion, up 5.5% year-over-year, but up 7% at constant currency.  GAAP diluted EPS was $0.78, above 23Q1’s $0.69 and my estimate of $0.77.  Non-GAAP EPS of $1.22 was above last year’s $1.08 and also…

Continue reading →